Pratik S. Multani Sells 8,850 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) insider Pratik S. Multani sold 8,850 shares of ORIC Pharmaceuticals stock in a transaction on Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $73,278.00. Following the completion of the transaction, the insider now owns 46,765 shares of the company's stock, valued at approximately $387,214.20. This trade represents a 15.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

ORIC Pharmaceuticals Trading Up 0.1 %

Shares of ORIC traded up $0.01 during midday trading on Tuesday, reaching $8.25. The stock had a trading volume of 321,133 shares, compared to its average volume of 500,967. The company's 50-day moving average is $9.35 and its 200 day moving average is $9.37. ORIC Pharmaceuticals, Inc. has a 12-month low of $6.33 and a 12-month high of $16.65. The company has a market capitalization of $582.20 million, a price-to-earnings ratio of -4.62 and a beta of 1.13.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.01). Research analysts forecast that ORIC Pharmaceuticals, Inc. will post -1.84 EPS for the current fiscal year.

Institutional Investors Weigh In On ORIC Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ORIC. Millennium Management LLC lifted its stake in shares of ORIC Pharmaceuticals by 297.4% in the 2nd quarter. Millennium Management LLC now owns 782,299 shares of the company's stock valued at $5,531,000 after acquiring an additional 585,447 shares during the last quarter. First Turn Management LLC lifted its stake in shares of ORIC Pharmaceuticals by 38.1% in the 2nd quarter. First Turn Management LLC now owns 1,515,960 shares of the company's stock valued at $10,718,000 after acquiring an additional 418,389 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of ORIC Pharmaceuticals by 190.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 466,662 shares of the company's stock valued at $3,299,000 after acquiring an additional 305,860 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of ORIC Pharmaceuticals by 152.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 410,229 shares of the company's stock valued at $4,205,000 after acquiring an additional 247,863 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of ORIC Pharmaceuticals by 26.1% in the 3rd quarter. Franklin Resources Inc. now owns 950,459 shares of the company's stock valued at $9,067,000 after acquiring an additional 196,804 shares during the last quarter. Institutional investors own 95.05% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on ORIC shares. Wells Fargo & Company started coverage on ORIC Pharmaceuticals in a research report on Thursday, October 31st. They set an "overweight" rating and a $20.00 target price for the company. HC Wainwright restated a "buy" rating and set a $21.00 target price on shares of ORIC Pharmaceuticals in a research report on Monday, November 4th. Stifel Nicolaus started coverage on ORIC Pharmaceuticals in a research report on Friday, September 6th. They set a "buy" rating and a $20.00 target price for the company. Wedbush restated an "outperform" rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a research report on Tuesday, November 12th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of ORIC Pharmaceuticals in a research report on Monday, September 23rd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $18.29.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.